Literature DB >> 21597974

Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas.

Filip Gabalec1, Martin Beranek, David Netuka, Vaclav Masopust, Jiri Nahlovsky, Tomas Cesak, Josef Marek, Jan Cap.   

Abstract

Clinically non-functioning pituitary adenomas account for about one-third of pituitary tumors. The majority of them are pathologically classified as gonadotropinomas or null-cell adenomas without hormonal expression. The rest represent silent corticotroph adenomas and plurihormonal tumors. Conservative therapy with dopamine agonists is effective in some cases only depending on the expression of dopamine 2 receptors (D2R). The aim of this study was to quantitatively estimate D2R expression in clinically non-functioning pituitary adenomas and correlate the results with adenoma type according to pathological classification. Out of the 87 adenomas investigated, 63 expressed gonadotropins, 7 were silent corticotroph adenomas, 7 were plurihormonal tumors, and only 6 did not express any pituitary hormone on immunohistochemical investigation. With the use of the reverse transcriptase PCR technique, D2R mRNA was expressed in all adenomas with very heterogeneous quantity. The expression was very low in corticotroph adenomas (relative median quantity after normalization to housekeeping gene 0.01) and lower in plurihormonal tumors (median 0.4) than in gonadotroph (median 1.3) and null-cell adenomas (median 1.9). The difference between corticotroph adenomas and plurihormonal tumors in comparison with other pathological types was statistically significant. The expression of D2R did not depend on the presence or absence of gonadotropins. We conclude that D2R expression is very low in corticotroph adenomas and significantly lower in plurihormonal tumors. The positivity of gonadotropins does not predict the D2R quantity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21597974     DOI: 10.1007/s11102-011-0316-1

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  18 in total

1.  The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas.

Authors:  Jan Cap; Jaroslav Cerman; Stanislav Nemecek; Martina Marekova; Vaclav Hana; Zdenek Frysak
Journal:  J Clin Neurosci       Date:  2003-07       Impact factor: 1.961

2.  Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.

Authors:  Rosario Pivonello; Carmela Matrone; Mariagiovanna Filippella; Luigi M Cavallo; Carolina Di Somma; Paolo Cappabianca; Annamaria Colao; Lucio Annunziato; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

Review 3.  The 2004 World Health Organization classification of pituitary tumors: what is new?

Authors:  Mubarak Al-Shraim; Sylvia L Asa
Journal:  Acta Neuropathol       Date:  2005-11-23       Impact factor: 17.088

Review 4.  Regulation of prolactin secretion at the level of the lactotroph.

Authors:  S W Lamberts; R M Macleod
Journal:  Physiol Rev       Date:  1990-04       Impact factor: 37.312

5.  Heterogeneous dopamine D2 receptor subtype messenger ribonucleic acid expression in clinically nonfunctioning pituitary adenomas.

Authors:  U Renner; T Arzberger; U Pagotto; S Leimgruber; E Uhl; A Müller; M Lange; A Weindl; G K Stalla
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

6.  Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.

Authors:  D Ferone; S Lastoria; A Colao; P Varrella; G Cerbone; W Acampa; B Merola; M Salvatore; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1998-01       Impact factor: 5.958

Review 7.  Clinically non-functioning pituitary adenoma.

Authors:  Craig A Jaffe
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

8.  Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine.

Authors:  J S Bevan; C W Burke
Journal:  Clin Endocrinol (Oxf)       Date:  1986-11       Impact factor: 3.478

Review 9.  Non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

Review 10.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

View more
  5 in total

1.  Commentary on "expression of dopamine 2 receptor subtypes mRNA in clinically nonfunctioning pituitary adenomas".

Authors:  Andrea Salmaggi; Sandro Lodrini
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

2.  DR2 blocker thioridazine: A promising drug for ovarian cancer therapy.

Authors:  Min Yong; Tinghe Yu; Si Tian; Shuaibin Liu; Jiao Xu; Jianguo Hu; Lina Hu
Journal:  Oncol Lett       Date:  2017-10-16       Impact factor: 2.967

Review 3.  Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review.

Authors:  Benjamin Voellger; Zhuo Zhang; Julia Benzel; Junwen Wang; Ting Lei; Christopher Nimsky; Jörg-Walter Bartsch
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.241

Review 4.  Dopamine Agonists for Pituitary Adenomas.

Authors:  Odelia Cooper; Yona Greenman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-21       Impact factor: 5.555

5.  Difference in miRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of miRNA in the Regulation of Corticosteroid Receptors.

Authors:  Beata J Mossakowska; Paulina Kober; Natalia Rusetska; Joanna Boresowicz; Maria Maksymowicz; Monika Pękul; Grzegorz Zieliński; Andrzej Styk; Jacek Kunicki; Tomasz Mandat; Mateusz Bujko
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.